Zobrazeno 1 - 10
of 423
pro vyhledávání: '"Yoshinobu, Iwasaki"'
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-5 (2022)
Abstract Background Although the RECOVERY trial showed that dexamethasone was efficacious for the treatment of coronavirus disease 2019 (COVID-19), its impact on the risk of pulmonary embolism (PE) and other serious procoagulant events was not assess
Externí odkaz:
https://doaj.org/article/af94603c904f42cd85662b762adb51a4
Publikováno v:
Thoracic Cancer, Vol 12, Iss 10, Pp 1625-1628 (2021)
Abstract We report the cases of two patients with secondary hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors, who were diagnosed using the recently developed HScore. The first patient presented with fever, cytopenia, and elev
Externí odkaz:
https://doaj.org/article/dd7de3862b714b2aba4b310cd955e49a
Autor:
Hidenori Takahashi, Yoshinobu Iwasaki, Takayasu Watanabe, Naoki Ichinose, Yasusei Okada, Akito Oiwa, Takehiro Kobayashi, Mariko Moriya, Toshimi Oda
Publikováno v:
International Journal of Infectious Diseases, Vol 100, Iss , Pp 283-285 (2020)
• The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is spreading globally. However, clinically effective antiviral treatments are not established. Favipiravir may prevent pneumonia and acute respiratory distress syndrome agg
Externí odkaz:
https://doaj.org/article/edf95f00b55745b9a352394a86a1ee9a
Publikováno v:
Respirology Case Reports, Vol 8, Iss 8, Pp n/a-n/a (2020)
Abstract We report a patient with idiopathic hypereosinophilic syndrome (I‐HES) who achieved remission with benralizumab after relapsing on mepolizumab. An 83‐year‐old man was admitted to Showa General Hospital after presenting with hypoxaemia
Externí odkaz:
https://doaj.org/article/e7664c04ae0f4a8fb1cfdbc34fedd7a5
Autor:
Hidenori Takahashi, Tomohiro Koiwa, Akira Fujita, Takayuki Suzuki, Amane Tagashira, Yoshinobu Iwasaki
Publikováno v:
Respiratory Medicine Case Reports, Vol 30, Iss , Pp 101097- (2020)
Treatments using immune checkpoint inhibitors such as pembrolizumab lead to immune mediated adverse effects including hemophagocytic lymphohistiocytosis (HLH). Herein, we present a case where HLH developed after pembrolizumab administration, which wa
Externí odkaz:
https://doaj.org/article/1061d4fcce984d1097c51cbb5155023b
Publikováno v:
Thoracic Cancer, Vol 12, Iss 10, Pp 1625-1628 (2021)
Thoracic Cancer
Thoracic Cancer
We report the cases of two patients with secondary hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors, who were diagnosed using the recently developed HScore. The first patient presented with fever, cytopenia, and elevated live
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5366d36536f2b8ffaba70d2ca9ace0c0
https://doaj.org/article/dd7de3862b714b2aba4b310cd955e49a
https://doaj.org/article/dd7de3862b714b2aba4b310cd955e49a
Publikováno v:
Kansenshogaku Zasshi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::655674b5abfb3bab7db3c1cb6665007f
https://doi.org/10.11150/kansenshogakuzasshi.94.608
https://doi.org/10.11150/kansenshogakuzasshi.94.608
Publikováno v:
Respirology Case Reports
See related Letter.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a118ba7e8317157877f53ad1c640968
https://doi.org/10.1002/rcr2.708
https://doi.org/10.1002/rcr2.708
Publikováno v:
BMC infectious diseases. 22(1)
Background Although the RECOVERY trial showed that dexamethasone was efficacious for the treatment of coronavirus disease 2019 (COVID-19), its impact on the risk of pulmonary embolism (PE) and other serious procoagulant events was not assessed. Case
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49e04d3bdf6beed0eb6f0736e0b0ee65
https://pubmed.ncbi.nlm.nih.gov/35317729
https://pubmed.ncbi.nlm.nih.gov/35317729
Publikováno v:
Respirology Case Reports, Vol 8, Iss 8, Pp n/a-n/a (2020)
Respirology Case Reports
Respirology Case Reports
We report a patient with idiopathic hypereosinophilic syndrome (I‐HES) who achieved remission with benralizumab after relapsing on mepolizumab. An 83‐year‐old man was admitted to Showa General Hospital after presenting with hypoxaemia and multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d7f3c66c4c3bfaea94d43b2140ab475
https://doaj.org/article/e7664c04ae0f4a8fb1cfdbc34fedd7a5
https://doaj.org/article/e7664c04ae0f4a8fb1cfdbc34fedd7a5